Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Durvalumab + Trabectedin
Indication/Tumor Type ovarian carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive ovarian carcinoma predicted - sensitive Durvalumab + Trabectedin Case Reports/Case Series Actionable In a Phase Ib trial (TRAMUNE), Yondelis (trabectedin) plus Imfinzi (durvalumab) demonstrated safety and resulted in an objective response rate of 21.4% (3/14, all partial responses), 3- and 6-month progression-free rates of 42.9% and 42.9%, a 1-year progression-free survival (PFS) rate of 7.1%, and a 1-year overall survival rate of 57.1% in patients with ovarian carcinoma, with an improved PFS for patients with CD274 (PD-L1) expression (6.8 mo vs 1.3 mo) (PMID: 34965951; NCT03085225). 34965951
PubMed Id Reference Title Details
(34965951) Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. Full reference...